Utreglutide

AssetAlso GL0034

Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, improve glycemic control, and reduce body weight.

Stage: Human trials
Modality: Peptide
Target: Insulin/IGF-1 signalling; 2
Indications: 0
Trials: 1
Developer

Indications

2

Obesity
Human trials, doi.org, 5 Jun 2026
Type 2 diabetes
Human trials, doi.org, 5 Jun 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets3
Competitors12
Signals3

Every asset’s record: target, stage, trials and the evidence behind it.